This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1. (currently amended) A method of determining a biological sample component expression pattern for a biological sample, comprising:

applying a biological sample to an affinity support comprising a ligand coupled to a biological sample-compatible hydrophilic matrix, said ligand comprising a backbone having a plurality of affinity property groups and hydrophilic groups pendent therefrom, and said ligand having a binding affinity characterized by a specificity for one or more components of the biological sample that is intermediate between charge-based and antibody-based ligands and being configured to at least partially resolve the one or more components of said biological sample;

<u>chromatographically</u> resolving the <u>at least</u> one <u>or more components</u> eomponent of the biological sample to provide thereby an enriched fraction; and

determining a biological sample component expression pattern for the biological sample using the enriched fraction in at least one of an electrophoretic and a mass spectroscopic technique.

- 2. (currently amended) The method of claim 1, wherein the <u>one or more</u> biological sample components comprise proteins.
- 3. (currently amended) The method of claim 1, wherein the <u>one or more</u> biological sample components comprise nucleotides.
- (currently amended) The method of claim 1, wherein said hydrophilic ligand comprises:
 a peptoid backbone; and
 - a plurality of affinity property groups and hydrophilic groups being pendent from said peptoid backbone.
- 5. (original) The method of claim 4, wherein said hydrophilic groups are intercalated with said affinity property groups.
- 6. (original) The method of claim 5, wherein said hydrophilic groups alternate with said affinity property groups along said peptoid backbone.

USSN: 09/704,422

- 7. (original) The method of claim 6, wherein said affinity property groups are selected from the group consisting of alkyl, (cycloalkyl)alkyl, (cycloheteroalkyl)alkyl, aralkyl, and heteroaralkyl, each substituted optionally from the group consisting of oxo, thia, halo, amino, hydroxy, cyano, nitro, thio, aminocarbonyl, carboxy, and imino.
- 8. (original) The method of claim 7, wherein said affinity property groups are selected from the group consisting of methyl, hydroxymethyl, prop-2-yl, 2-methylpropyl, pyrrolidylmethyl, methylthioethyl, 1-hydroxyethyl, thiomethyl, aminocarbonylmethyl, aminocarbonylethyl, carboxymethyl, carboxyethyl, 4-aminobutyl, and 3-guanidinopropyl, guanidinoaryl, hydroxyaryl, amidoalkyl, phosphonyl alkyl, phosphonyl aryl, oligoether, and polyhydroxyalkyl.
- 9. (original) The method of claim 7, wherein said affinity property groups are selected from the group consisting of optionally substituted aralkyl and heteroaralkyl.
- 10. (original) The method of claim 9, wherein said affinity property groups are selected from the group consisting of phenylmethyl, hydroxyphenylmethyl, imidazolylmethyl, purinylmethyl, pyrimidinylmethyl, and indolylmethyl.
- 11. (currently amended) The method of claim 7, wherein said affinity groups are selected from the group consisting of optionally substituted amonioalkyl, and trialkylamonioalkyl.
- 12. (original) The method of claim 7, wherein said affinity property groups are optionally substituted carboxylatoalkyl.
- 13. (original) The method of claim 4, wherein said hydrophilic groups are selected from the group consisting of alkyloxyalkylenyl, aminoalkyl, alkylaminoalkyl, quaternary ammoniumalkyl, hydroxyalkyl, thioalkyl, alkylthioalkylenyl, carboxyalkyl, alkyloxycarbonylalkyl, and aminocarbonylalkyl.
- 14. (currently amended) The method of claim <u>4</u> 13, wherein said hydrophilic group is alkyloxyalkyl.
- 15. (currently amended) The method of claim <u>4</u> 14, wherein said hydrophilic group is selected from the group consisting of methoxyethyl, hydroxyethyl, 1-hydroxyethyl-2-hydroxyethyl, and 2,3-dihydroxypropyl.
- 16. (original) The method of claim 4, wherein about 50% of said pendant groups are affinity property groups.
- 17. (original) The method of claim 16, wherein about 33% of said pendant affinity property groups have a common affinity property.

USSN: 09/704,422

Attorney Docket No.: 1613.003/CHIRP012

- 18. (original) The method of claim 16, wherein about 67% of said pendant affinity property groups have a common affinity property.
- 19. (original) The method of claim 16, wherein about 100% of said pendant affinity property groups have a common affinity property.
- 20. (original) The method of claim 4, wherein said affinity property groups and said hydrophilic groups are pendant from nitrogen atoms in the backbone.
- 21. (original) The method of claim 4, wherein said biological sample is derived from a homogeneous source.
- 22. (original) The method of claim 21, wherein said homogeneous source is a cell line.
- 23. (original) The method of claim 4, wherein said biological sample is derived from a heterogeneous source.
- 24. (original) The method of claim 23, wherein said heterogeneous source is one or more tissue samples.
- 25. (previously amended) The method of claim 23, wherein said heterogeneous source is one or more blood samples.
- 74. (previously added) The method of claim 1, wherein the intermediate binding affinity is characterized by the ligand interacting with the components of the biological sample by a combination of non-specific molecular forces consisting essentially of ionic, van der Waal's and hydrogen bond interactions.
- 75. (previously added) The method of claim 4, wherein the ligand is selected from the group consisting of the following:

USSN: 09/704,422

Attorney Docket No.: 1613.003/CHIRP012

OWE OWE OWE OWE OWE OWE OWE NH, OME CO3HOME NH, OME CO2HOME NH, OME CO3HOME

NH, OME CO3HOME NH, OME CO3HOME NH, OME CO3HOME

NH, OME CO3HOME NH, OME CO3HOME NH, OME CO3HOME

NH, OME CO3HOME NH, OME CO3HOME NH, OME CO3HOME NH₂ QMe QMe NH₂ QMe QMe NH₃ QMe QMe ANH₃ QMe ANH₃ QMe QMe A NHZ DWO DWO NHZ DWO DWO NHZ DWO DWO CO2H DMG CO2H OMG CO2H DMG CO2H DMG CO3H DMG CO3

Attorney Docket No.: 1613.003/CHIRP012